Humana (HUM) Stock Rockets 12% on Medicare Advantage Payment Rate Revelation

Key Takeaways

• CMS confirmed a 2.48% Medicare Advantage payment rate for 2027, dramatically higher than the 0.09% initially proposed three months ago.
• Humana (HUM) shares rocketed 12% in after-hours trading, while UnitedHealth (UNH) and CVS Health (CVS) climbed more than 6% during premarket hours.
• The approved rate will inject over $13 billion in additional Medicare Advantage revenue to health insurers throughout 2027.
• Other managed care providers joined the rally, with Molina Healthcare (MOH) advancing 7% and Centene (CNC) gaining 4%.
• Mizuho’s Jared Holz characterized the rate as “certainly better than the government’s initial rate decision,” though cautioned it isn’t extraordinary in isolation.

Humana (HUM) shares launched approximately 11% higher on Tuesday morning, responding to Monday evening’s revelation of the official 2027 Medicare Advantage reimbursement rates.

Humana Inc., HUM

The approved 2.48% rate represents a dramatic improvement over the 0.09% preliminary rate unveiled in January, which shocked the healthcare industry and triggered selling pressure across insurer equities.

The CMS decision translates to private health insurance companies receiving upwards of $13 billion in supplementary Medicare Advantage reimbursements from federal coffers during 2027.

UnitedHealth (UNH) and CVS Health (CVS), which owns Aetna, both surged over 6% before the opening bell Tuesday. Elevance Health (ELV) jumped approximately 5%. Hospital operators and managed care organizations likewise benefited, with Molina Healthcare (MOH) climbing 7% and Centene (CNC) advancing 4%.

The equity surge followed an extended period of industry advocacy, with insurers and industry associations contending that January’s proposal ignored escalating medical expenditures. The Better Medicare Alliance characterized the near-zero preliminary rate as effectively a “cut,” highlighting that medical cost inflation has been running between 7% and 9% year-over-year.

Key Modifications in the Final Decision

CMS implemented multiple technical revisions beyond the primary rate adjustment. Beginning in 2027, the department will eliminate diagnosis information from unlinked chart review documentation when determining risk scores, though creating an exception for enrollees transferring between Medicare Advantage carriers.

The department indicated this modification will disproportionately affect plans that depend extensively on chart reviews to capture patient diagnoses and secure elevated reimbursements. CMS additionally refreshed the Part D risk adjustment framework to incorporate modifications mandated by the Inflation Reduction Act.

Why This Rate Matters

Medicare Advantage serves approximately 35 million Americans and has experienced consistent expansion, now exceeding participation in traditional government-administered Medicare. The final reimbursement rate determines how more than half a trillion dollars circulates through private health coverage annually, establishing it as among the most scrutinized metrics within the health insurance industry.

The calculation incorporates variables including fundamental cost escalation, 2026 Star Ratings governing quality incentive payments, and risk adjustment formula modifications. CMS verified it will maintain the 2024 Medicare Advantage risk adjustment framework for 2027.

Bipartisan congressional concern regarding Medicare Advantage expenditures had introduced additional unpredictability into the rate-setting process. Lawmakers across party lines have questioned insurer documentation methodologies that can generate elevated payments for enrollees with more comprehensive diagnosis records. The Biden administration’s CMS had already begun restricting those reimbursements, and January’s proposal under the Trump administration demonstrated that oversight would persist.

The post Humana (HUM) Stock Rockets 12% on Medicare Advantage Payment Rate Revelation appeared first on Blockonomi.